Drug Profile
TSG 6 - Bessor Pharma
Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Texas A&M University
- Developer Bessor Pharma; Texas A&M University
- Class Anti-inflammatories; Eye disorder therapies; Immunotherapies
- Mechanism of Action Immunomodulators; Inflammasome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries; Ocular inflammation
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for preclinical development in Brain injuries in USA
- 28 Feb 2019 No recent reports of development identified for preclinical development in Ocular-inflammation in USA